Q1 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF) – Roth Capital issued their Q1 2025 earnings per share estimates for Cresco Labs in a report released on Thursday, March 13th. Roth Capital analyst W. Kirk anticipates that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.04) EPS.

Separately, Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Cresco Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.00.

Cresco Labs Price Performance

Shares of OTCMKTS CRLBF opened at $0.73 on Monday. Cresco Labs has a fifty-two week low of $0.70 and a fifty-two week high of $2.60. The business has a 50 day moving average price of $0.88 and a two-hundred day moving average price of $1.19. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. The firm has a market cap of $358.29 million, a PE ratio of -3.67 and a beta of 1.79.

Cresco Labs (OTCMKTS:CRLBF) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The firm had revenue of $176.00 million during the quarter, compared to analyst estimates of $172.10 million.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.